Clovis Oncology Announces Third Quarter 2017 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Clovis Oncology (CLVS) Misses Q3 EPS by 2c
November 1, 2017 4:10 PM EDTClovis Oncology (NASDAQ: CLVS) reported Q3 EPS of ($1.24), $0.02 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $21.12 million.
Clovis had $628.0 million in cash, cash equivalents and available-for-sale securities as of September 30, 2017. Cash used... More
